{'fraction_non_alphanumeric': 0.024250159540523293, 'fraction_numerical': 0.021059349074664963, 'mean_word_length': 5.4526748971193415, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The influence of oral statin medications on progression of glaucomatous visual field loss: A propensity score analysis

ABSTRACT Purpose: The purpose of this study was to examine the association between oral statin use and the progression of open angle glaucoma. Methods: Medical records of 847 Veterans were reviewed to collect statin use history, record demographic and comorbid medical conditions, and review visual fields. Visual field progression was judged by an ophthalmologist masked to statin use history. Progression rates in a propensity score matched cohort were compared between statin users and nonusers using McNemar’s test with the propensity model derived using associated medical and demographic factors. Results: The mean length of observation was 1324 days with a standard deviation of 464 days. Thirty-one per cent of Veterans demonstrated glaucomatous progression in at least one eye, 49% did not demonstrate progression, and 20% were indeterminate. Approximately 74% of subjects had previously used a statin, with this group having heavier burdens of several comorbid medical conditions and less severe baseline glaucoma than nonusers. The matched cohort was 196 statin users and 196 nonusers, each with similar baseline characteristics (standardised differences <0.10). Progression rates were 35% for statin users compared to 56% for nonusers in the matched cohort (McNemar’s p<0.001). Conclusions: In this population of Veterans, glaucoma patients with any history of statin use have lower visual field progression rates than statin nonusers.